Vivos Therapeutics, Inc. NASDAQ: VVOS
Vivos Therapeutics, Inc.
First Quarter 2022 Earnings Call
An Important Breakthrough in the Treatment for Mild-to-Moderate Obstructive Sleep Apnea
Vivos offers a multidisciplinary treatment protocol that uses nonsurgical, noninvasive, and cost-effective oral appliance technology prescribed by trained dentists and medical professionals to treat dentofacial abnormalities and/or mild-to-moderate OSA. This revolutionary treatment is called The Vivos Method.
Latest Stock Information
Listen to Kirk Huntsman and Brad Amman at the
34th Annual Roth Conference
Download the Vivos Investor Presentation
Fast Company Selects Vivos Therapeutics for 2022
“World’s Most Innovative Companies” List
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Our leadership team is devoted to a singular mission: to rid the world of sleep apnea.
Call Scheduled for Today, Thursday, March 31, 2022 at 5:00 pm ET HIGHLANDS RANCH Colorado, March 31, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics,...
Pioneer in Treating Dentofacial Abnormalities and / or Mild-to-Moderate Obstructive Sleep Apnea Ranks Among Top 10 Most Innovative Medical Device...
Vivos Therapeutics Rebrands Proprietary Clinical Protocol for Treating Patients with Breathing and Sleep Disorders
The Vivos Method’s Proprietary Combination of Multidisciplinary Protocols and Oral Appliances Featured on New Corporate Website HIGHLANDS RANCH...